1cP-MiPLA Blotters – 200 mcg

 25,00 350,00

Other Name(s): 1-Cyclopropionylmethylisoproyllysergamide
IUPAC Name: (6aR,9R)1-Cyclopropionyl-N-methyl-N-isopropyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide


Formula: C24H29N3O
Molar Mass: 391.5 g/mol
SKU: N/A Category:



DISCLAIMER: The following text is for educational purposes only, our products are strictly for research purposes and not for human consumption!

The origin of 1cP-MiPLA:

1-Cyclopropionyl-N-methyl-N-isopropyllysergamide, commonly known as 1cP-MiPLA, belongs to the lysergamide class of psychedelic compounds. It is closely related to MiPLA and is suspected to potentially act as a prodrug for MiPLA. However, it’s important to note that there is currently a lack of scientific data and a limited number of anecdotal reports to confidently support this hypothesis.


1cP-MiPLA emerged as a novel research chemical around 2020 or 2021. It was purportedly first synthesized by individuals like Skyler Ulrich or a chemist/group operating under the name Gerstmann and subsequently made available on various research chemical markets. Alongside other novel lysergamides such as 1cP-AL-LAD, it garnered attention within this community.


User reports of 1cP-MiPLA describe its effects as being similar to those of MiPLA. While some anecdotal accounts suggest minor differences between the two substances, it’s essential to emphasize that this doesn’t necessarily negate the possibility that 1cP-MiPLA might indeed serve as a true prodrug for MiPLA. Many of their effects appear to be either identical or very similar based on these reports.


The parent drug MiPLA was initially discovered as a result of Albert Hofmann’s investigations during the original structure-activity research for LSD, although specific references or citations for this claim are not provided. More recently, it has undergone more in-depth research conducted by a team led by David E. Nichols at Purdue University, although this information is also lacking specific citations.


Alexander Shulgin, a prominent figure in the field of pharmacology, documented MiPLA and its effects in his “Pharmacology Notes #9” and “Pharmacology Notes C.” According to Shulgin’s observations, human subjects who were administered doses of MiPLA ranging from 180 to 300 μg reported psychedelic effects similar to those induced by LSD. This suggests that MiPLA is approximately two to three times less potent than LSD in producing these psychedelic effects.



How 1cP-MiPLA works in the brain:

1cP-MiPLA and its parent molecule MiPLA are structurally related to LSD (lysergic acid diethylamide), a well-studied psychedelic substance. LSD primarily affects the brain by interacting with the serotonin system, specifically the serotonin 5-HT2A receptor., it is believed that 1cP-MiPLA is about half as potent compared to LSD, resulting in less intense effect and also a shorter duration Here’s a general idea of how psychedelic substances like LSD and 1cP-MiPLA work in the brain:

  1. Serotonin Receptor Activation: 1cP-MiPLA is believed to exert their effects by binding to and activating the serotonin 5-HT2A receptors in the brain. This receptor is a subtype of the serotonin receptor family.
  2. Altered Neurotransmission: Activation of the 5-HT2A receptor leads to altered neurotransmission, particularly in areas of the brain associated with perception, mood, and cognition. This disruption in normal serotonin signaling is thought to underlie the psychedelic effects.
  3. Increased Neural Connectivity: Psychedelics like LSD are associated with increased neural connectivity in the brain, leading to changes in perception, thought patterns, and consciousness. This heightened connectivity is believed to contribute to the characteristic “mind-expanding” effects of psychedelics.
  4. Modulation of Mood and Perception: Activation of the serotonin system by psychedelics can lead to profound changes in mood, perception, and thought processes. Users often report altered sensory experiences, enhanced emotions, and even mystical or spiritual experiences.

It’s worth emphasizing that the specific mechanisms of action and the effects of MiPLA may not be exactly the same as those of LSD, even though they share structural similarities. The differences in chemical structure can lead to variations in how these substances interact with receptors and neurotransmitter systems in the brain.

Research on the pharmacology and neurobiology of MiPLA and other novel psychedelics is ongoing, and new findings may emerge in the future. However, given the limited available data, caution and responsible use are essential when dealing with these substances, as their effects and safety profiles are not well-established. Always seek guidance from qualified healthcare professionals if you have questions or concerns about the use of psychedelics.



Traditional and modern use of 1cP-MiPLA:

MiPLA is a relatively new and lesser-known compound in the world of psychedelics. It is part of the lysergamide class of substances and is structurally related to LSD (lysergic acid diethylamide). While there isn’t extensive information available about its use and user demographics, the next summary provides some general insights into the types of individuals who might be interested in or experimenting with substances like MiPLA:

  1. Researchers: Some researchers in the field of pharmacology and neuroscience may use MiPLA in laboratory studies to better understand its effects on the brain and its potential therapeutic applications. This type of research is typically conducted in controlled and regulated environments.
  2. Enthusiasts: There is a subset of individuals who are enthusiasts of novel or rare psychoactive compounds. These enthusiasts may be interested in trying MiPLA out of curiosity or to explore its subjective effects. However, it’s important to note that the use of novel substances carries inherent risks, as their safety profiles are often not well-established.
  3. Psychonauts: Some individuals who consider themselves “psychonauts” engage in self-experimentation with various psychedelics to explore altered states of consciousness, gain insight into their minds, or have mystical or spiritual experiences. MiPLA could potentially be of interest to this group.
  4. Alternative Therapy Seekers: In recent years, there has been growing interest in the potential therapeutic benefits of psychedelics, including substances like LSD. Some individuals who are seeking alternative therapies for conditions such as depression, anxiety, or post-traumatic stress disorder (PTSD) may be interested in exploring MiPLA as a potential treatment option, although its efficacy and safety for such purposes would require rigorous scientific investigation.

It’s important to emphasize that the use of MiPLA, like any psychoactive substance, should be approached with caution and responsibility. Novel compounds often lack the extensive safety and efficacy data associated with more established medications. Moreover, the legal status of MiPLA may vary by country or region, so individuals should be aware of and comply with relevant laws and regulations.


Additional information


1 blotter, 5 blotters, 10 blotters, 25 blotters, 100 blotters